Ensure Sterility and Enable Scalable Manufacturing

Our cGMP cytokines in single-use bags are designed for convenience and performance. Stable at 2–8°C for up to one year, our CSS cytokines enable plug-and-play integration into any immune cell manufacturing system, no thawing required.


Backed by FDA Drug Master Files, our CSS cytokines support smooth regulatory submissions and scale-up from preclinical to commercial production.


Currently available in IL-2, IL-7, and IL-15, with flexible fill volumes and concentrations to meet your specific manufacturing needs.

Performance-Ready for Closed System Workflows

Closed System Solutions (CSS)™ Cytokines Now Available

Catalog Number: AR1045-0010
Format: 1 MIU Bag
Source: E.coli
Stability: Under Long Term Stability Program

Catalog Number: AR1045-0020
Format: 2 MIU Bag
Source: E.coli
Stability: Under Long Term Stability Program

Catalog Number: AR1050-0020
Format: 15 MIU Bag
Source: E.coli
Stability: Under Long Term Stability Program
Catalog Number: AR1013-0100
Format: 100 ug Bag (10 mL Fill)
Source: E.coli
Stability: Under Long Term Stability Program
Catalog Number: AR1003-0050
Format: 50 ug Bag (5 mL Fill)
Source: E.coli
Stability: Under Long Term Stability Program
Product Name
Catalog Number
Format
Source
Stability
rHu IL-2
AR1045-0010
1 MIU Bag
E.coli
Under Long Term Stability Program
AR1045-0020
2 MIU Bag
E.coli
Under Long Term Stability Program
AR1050-0020
15 MIU Bag
E.coli
Under Long Term Stability Program
rHu IL-7
AR1013-0100
100 ug Bag (10 mL Fill)
E.coli
Under Long Term Stability Program
rHu IL-15
AR1003-0050
50 ug Bag (5 mL Fill)
E.coli
Under Long Term Stability Program

NOTICE: Catalog #’s AR1045-0010, AR1045-0020, AR1050-0020, AR1013-0100, and AR1003-0050 are patent pending.

Say goodbye to wasted time and human error

Our liquid cytokines offer the quality, consistency, and reliability needed to support your immune cell therapy workflows. Simplify your process with ready-to-use cytokines in weldable bags.

  • Reduces unnecessary complexity by eliminating reconstitution
  • Multiple tubing options allow for seamless integration into closed systems
  • Reduces human labor and error

Reducing the Complexity, Time, Risk, and Cost

We designed our CSS product line from the ground up to address the evolving challenges in cell manufacturing faced by T cell therapeutic developers. Read our blog post to learn why we created the CSS line—and how developers are now benefiting from it.



Functional Comparison with Lyophilized II-7 And II-15 Using Healthy Donors Derived T-Cells

Figure: IL-7 and IL-15 CSS were compared with their lyophilized forms with cells isolated from healthy donors. Cryo-preserved apheresis from two healthy donors were thawed, selected, and activated. Culture media were supplemented with reconstituted lyophilized powders of IL-7 and IL-15 or liquid formulation of CSS. Final concentration of IL-7 and IL-15 was 600 IU/mL and 100 IU/mL, respectively. Media was also supplemented with 100 IU/mL of IL-2. Prepared media were stored at 2–8°C and used 12 days post-cytokine addition. Cells were assessed for the percentage of CAR+ (A) and CD4+:CD8+ ratio (B) at harvest. Harvested cells were cryopreserved to mimic the storage of the drug product. Several days after cryopreservation, cells were thawed and assessed for viability (C).